(RTTNews) - On Wednesday, Pharming Group N.V. (PHAR) announced positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation linked to altered PI3Kdelta signa
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.